Trial Profile
A Phase 1 Trial of RO5126766 (CH5126766) in Patients With Advanced KRAS-Mutant Lung Adenocarcinomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Avutometinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 02 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 01 Dec 2021 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.